These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia]. Tauchi T; Oyashiki K Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118 [No Abstract] [Full Text] [Related]
11. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate]. Chen SS Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242 [No Abstract] [Full Text] [Related]
13. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003. Marcucci G; Perrotti D; Caligiuri MA Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391 [No Abstract] [Full Text] [Related]
14. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations. Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667 [TBL] [Abstract][Full Text] [Related]
16. Trends in the management of chronic myelogenous leukemia. Kantarjian H J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S41-5. PubMed ID: 16280112 [No Abstract] [Full Text] [Related]
17. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868 [No Abstract] [Full Text] [Related]